‌

US Patent 9567399 Antibodies and immunocytokines

Patent 9567399 was granted and assigned to Kymab on February, 2017 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Nikole Sandy0

Cassandra van Krinks0

Ian Kirby0

Jamie Campbell0

Miha Kosmac0

Stephen D. Gillies0

Steve Arkinstall0

Thomas Gallagher0

...

Date of Patent

February 14, 2017

0

Patent Application Number

152115040

Date Filed

July 15, 2016

0

Patent Citations Received

US Patent 11850262 Compositions and methods for CAR T cell therapy

0

US Patent 11858996 Anti-ICOS antibodies

0

US Patent 11884720 Antibody constructs for MSLN and CD3

0

US Patent 12134648 Dual specificity antibodies to human PD-L1 and PD-L2 and methods of use therefor

0

US Patent 11759480 Compositions and methods for CAR T cell therapy

US Patent 11976128 Human PD-L2 antibodies and methods of use therefor

0

US Patent 11753479 Nucleic acids encoding anti-OX40L antibodies

US Patent 12103976 Fc binding fragments comprising a CD137 antigen-binding site

0

...

Patent Primary Examiner

0

Patent abstract

The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 9567399 Antibodies and immunocytokines

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.